Ascent is lined up to copy 1 of the blockbuster drugs on this tracker, which earned $6.0B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Ascent's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Xtandi | Astellas / Pfizer | Generic | 2027 | Settled in 2025, terms confidential | ≈$6.0B |
Each drug page lists sources for these entries. Brand sales show the size of the market, not Ascent's share of it.